



MEDICAL THERAPIES AND PHARMACOLOGY

TREATMENT OF LOCALLY ADVANCED BASAL CELL CARCINOMA WITH COMMONLY USED ANTI-FUNGAL – ITRACONAZOLE

Magdalena Ciazynska⁽¹⁾ - Joanna Narbutt⁽²⁾ - Aleksandra Lesiak⁽²⁾

Department Of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre For Oncology And Traumatology, Department Of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre For Oncology And Traumatology, Łódź, Poland⁽¹⁾ - Department Of Dermatology, Pediatric Dermatology And Dermatological Oncology, Medical University Of Lodz, Department Of Dermatology, Pediatric Dermatology And Dermatological Oncology, Medical University Of Lodz, Łódź, Poland⁽²⁾

Background: Basal cell carcinoma (BCC) is the most common type of skin cancer with most of the forms resulting from disorder of hedgehog pathway activation. Recently the treatment of advanced form of BCC has been revolutionized with the discovery of the hedgehog signaling pathway. The aim of this study was to present and review the effectiveness of a systemic broad-spectrum antifungal, as a potent antagonist of the hedgehog signaling pathway – itraconazole to treat locally advanced BCCs based on clinical response and tolerability of our patient.

Observation: Itraconazole is promising anticancer treatment option also via several other mechanisms to prevent tumor growth, including prevention of angiogenesis, decreased endothelial cell proliferation, induction of autophagocytosis and cell cycle arrest. In our opinion, itraconazole appears to be effective, well tolerated, oral, treating therapy of locally advances BCCs of patients who may not be suitable candidates for surgical management or radiotherapy or who is disqualified from treatment with vismodegib or sunitinib or even progression after using these therapies.

Key message: We present case of locally advanced BCC, with stabilization in imaging studies during itraconazole treatment with clinical signs of wound healing and scientifically reduced at the first assessment after one month. The patient continued the treatment of itraconazole with no drug-related side effects.

